- Home
- NVCR vs CVAC Comparison
NVCR vs CVAC Comparison
Compare NVCR & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVCR | CVAC |
|---|---|---|
| Founded | 2000 | 2000 |
| Country | Switzerland | Germany |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NVCR | CVAC |
|---|---|---|
| Price | $12.11 | $5.14 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 3 |
| Target Price | ★ $28.42 | $6.83 |
| AVG Volume (30 Days) | ★ 1.9M | 1.7M |
| Earning Date | 10-30-2025 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 94.02 |
| EPS | N/A | ★ 0.94 |
| Revenue | ★ $642,269,000.00 | $83,000,117.00 |
| Revenue This Year | $9.75 | N/A |
| Revenue Next Year | $5.62 | $23.40 |
| P/E Ratio | ★ N/A | $5.47 |
| Revenue Growth | ★ 11.17 | N/A |
| 52 Week Low | $10.70 | $2.48 |
| 52 Week High | $34.13 | $5.72 |
Technical Indicators
Market Signals| Indicator | NVCR | CVAC |
|---|---|---|
| Relative Strength Index (RSI) | 50.47 | 43.12 |
| Support Level | $10.79 | $5.11 |
| Resistance Level | $11.86 | $5.23 |
| Average True Range (ATR) | 0.59 | 0.13 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 65.00 | 30.83 |
Price Performance
Historical ComparisonAbout NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.